Search Results

Terumo Cardiovascular, a global leader in cardiovascular surgery technologies, announced that the U.S. Food and Drug Administration has granted 510 clearance for the CDI OneView Monitoring System.

Bayer’s Kerendia, at the center of a $3 billion sales forecast, reduced the risk of cardiovascular death and heart failure in a Phase III trial.

Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in real-time iCMR cardiac ablation products, is pleased to announce that the Vision-MR Ablation Catheter 2.0 for Treatment of Type I Atrial Flutter (VISABL-AFL) IDE clinical trial, commenced with two procedures performed at the Cardiovascular Institute of South Paris (ICPS) (https://icps.fr).

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced plans to advance investigational plozasiran into a Phase 3 cardiovascular outcomes trial called CAPITAN.

Backed by Bain Capital, Cardurion Pharmaceuticals will use the Series B funds to advance two assets for heart failure and other cardiovascular conditions.

Vizient, Inc. examines pulsed field ablation technologies for atrial fibrillation and the role wearable monitoring devices can play in women’s cardiovascular health in the latest Medical Device Tech Watch.

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced its next-generation AI-enabled cardiovascular ultrasound platform to help speed up cardiac ultrasound analysis with proven AI technology and reduce the burden on echocardiography labs.

Milestone ® Pharmaceuticals Inc. today announced that it will present data on etripamil at the 30th Annual Cardiovascular Nursing Symposium held by the Preventive Cardiovascular Nurses Association on April 18-20th in Orlando, FL.